C11orf55 Inhibitors
C11orf55 inhibitors encompass a range of compounds that act on various signaling pathways to indirectly inhibit the functional activity of C11orf55. LY294002 and Wortmannin are both inhibitors of PI3K, a kinase that plays a central role in the PI3K/AKT signaling pathway. Inhibition of PI3K leads to reduced AKT phosphorylation, affecting downstream targets involved in cell survival and growth. Since C11orf55 is implicated in these cellular processes, its activity is indirectly diminished by these compounds. Rapamycin and AZD8055, as mTOR inhibitors, also exert indirect influence on C11orf55 by inhibiting the mTOR pathway, which is crucial for protein synthesis and cell proliferation.
The inhibition of C11orf55 through indirect chemical modulation involves a multifaceted approach that targets various upstream signaling molecules and pathways. LY294002 and Wortmannin, both PI3K inhibitors, lead to the abrogation of AKT phosphorylation, thereby attenuating the downstream signaling cascade that C11orf55 may be a part of. Inhibition of PI3K thus indirectly leads to the functional inhibition of C11orf55, as the activation of AKT is a critical step in numerous cellular processes including those associated with cell survival, growth, and proliferation, where C11orf55 could potentially play a role. Similarly, LY3214996, a specific inhibitor of ERK1/2, impedes the ERK signaling pathway which might be essential for the functional activity of C11orf55. By halting ERK1/2 activity, LY3214996 would suppress any ERK-dependent regulatory effects on C11orf55, thereby leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY294002 can diminish the PI3K/AKT signaling pathway. Given that C11orf55 is involved in this pathway, LY294002's inhibition of PI3K would result in reduced AKT activation, which is necessary for the full activation of C11orf55, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a known mTOR inhibitor. Inhibition of mTOR by Rapamycin would lead to decreased phosphorylation and activation of downstream targets that are essential for the cellular processes C11orf55 is involved in, thereby reducing C11orf55's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A specific inhibitor of p38 MAPK, SB203580 can suppress the MAPK pathway. By inhibiting p38 MAPK, SB203580 would reduce the phosphorylation of substrates downstream of p38 MAPK, which are potentially required for the optimal activity of C11orf55, thus indirectly inhibiting C11orf55 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, U0126 prevents the activation of ERK1/2 MAPKs. If C11orf55 operates downstream of or in conjunction with the ERK pathway, the inhibition of MEK by U0126 would result in decreased ERK activity and thus attenuate C11orf55's action. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As another PI3K inhibitor, Wortmannin would lead to a decrease in PI3K/AKT signaling. With PI3K inhibited, AKT cannot phosphorylate downstream targets that may be necessary for C11orf55's activity, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, PD98059 blocks the activation of MAPK/ERK. If C11orf55 is involved in the ERK signaling pathway, the inhibition of MEK by PD98059 would prevent the activation of ERK and consequently reduce the function of C11orf55. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 diminishes JNK signaling. C11orf55, if it is a part of the JNK pathway, would experience decreased activation due to the reduction in JNK-mediated signaling events, leading to its functional inhibition. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
Specifically inhibiting ERK1/2, LY3214996 would halt the ERK signaling pathway. With the ERK pathway inhibited, any potential involvement of C11orf55 in this pathway would be compromised, leading to a decrease in its activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
As a selective ATP-competitive inhibitor of mTOR, AZD8055 would suppress both mTORC1 and mTORC2 complexes. This would result in reduced activity of downstream effectors that are potentially linked to C11orf55's function, thereby inhibiting it. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
By inhibiting MEK1/2, Selumetinib prevents the activation of the downstream kinase ERK, which may play a role in C11orf55's activity. Thus, its inhibition would lead to decreased functional activity of C11orf55. | ||||||